Baird analyst Colleen Kusy reiterated an Outperform rating and $8.00 price target on Coherus Biosciences (NASDAQ: CHRS).The analyst commented: "Disappointing ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE